AgeneBio   Report issue

For profit Phase 3
Founded: Carmel IN United States (2008)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2018
NCT03486938
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

AgeneBio

Active Ingredients

Drugs in Phase 3 Trials (1)

levetiracetam (keppra) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 3)

Cognitive Dysfunction (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1